Navigation Links
Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma

Agilent Technologies Inc. (NYSE: A) today announced that its breakthrough Human Genome CGH Microarray technology will be used by researchers at Melbourne's Peter MacCallum Cancer Centre in a three-year study designed to better understand mesothelioma, a cancer found in the lining of the chest, the abdominal cavity and around the heart, usually caused by exposure to asbestos.

Due to its active mining and manufacturing of asbestos in the mid-1900s, Australia has the highest incidence of mesothelioma in the world. Rates of the disease have tripled in the past 20 years and are expected to peak about 2010. Diagnosis of this type of cancer is difficult, and patients are often not identified until the condition is quite advanced.

Agilent's new microarray techniques in comparative genomic hybridization (CGH) will allow researchers to rapidly and reliably identify genetic changes in tumorous cells. It is believed that specific genetic changes may accompany the onset and progression of the disease.

Dr. Andrew Holloway of the Peter MacCallum Cancer Centre said his team will work in conjunction with colleagues at The University of Western Australia, using Agilent's CGH microarray to provide a more thorough understanding of the genetic makeup of mesothelioma cells, which may ultimately lead to increased knowledge of the origins and development of this and other cancers.

"Agilent's CGH technology will allow us to study the entire genome in a manner that hasn't been possible in previous genomics research," said Holloway. "Upon completion, this project will produce the largest data set of its kind on mesothelioma in the world. We are very optimistic that it will give us a much clearer understanding and interpretation of this devastating disease."

"Agilent's new CGH microarray platform provides very high sensitivity, enabling researchers to detect small changes in chromosomes, including single copy deletions, which have previously been the most difficult to find," said Agilent Integrated Biology Solutions product manager David Tunks.

"We hope the outcome of this work will have a major effect on mesothelioma research," said Holloway. "The Australian economy will need $5 billion to fund the compensation, treatment and management of mesothelioma in the community, so this research is critical in working toward minimizing these costs, with the eventual hope of developing tools for earlier diagnosis and treatment."


'"/>

Source:Agilent


Related biology news :

1. Agilent Technologies releases automated literature search tool for biology researchers
2. Integration of Agilents MS technology, Proteome Systems software to help scientists in proteomics research
3. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
4. Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research
5. Agilent Technologies introduces high-capacity human protein removal system for proteomics research
6. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
7. Man and mouse share genome structures
8. Whole genome fine map of rice completed
9. Study finds more than one-third of human genome regulated by RNA
10. A bacterial genome reveals new targets to combat infectious disease
11. Scientists decipher genome of fungus that can cause life-threatening infections
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: